Add Formweb to your mobile device
System Formulary Update
Vibegron Tablet Therapeutic Interchange
Situation
Vibegron (Gemtesa) is a non-formulary beta-3 adrenergic receptor agonist indicated for overactive bladder. An evaluation of a therapeutic interchange to formulary equivalents is needed.
Background
System Formulary P&T Subcommittee and System P&T Committee voted to standardize the beta-3 adrenergic receptor agonist class in July 2020. However, vibegron was not accounted for in the original class review as it was approved by the FDA in December 2020.
Assessment
A therapeutic interchange for vibegron tablet built into Epic may improve workflow when converting patients to formulary products at admission.
Recommendation
|
Non-Formulary Order |
Formulary Equivalent Order |
|
Vibegron tablet 75 mg once daily |
Solifenacin Succinate tablet 5 mg once daily |
For the LMA build, recommend addition of verbiage to guide providers on how to not proceed with therapeutic interchange (i.e., decision to hold vibegron and not proceed with solifenacin). Similar format to mirabegron to solifenacin succinate therapeutic interchange LMA.